|Day Low/High||20.36 / 20.78|
|52 Wk Low/High||15.67 / 24.79|
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AIT, DSPG, FCAU, FOGO, HFC, KLIC, LINK, MGLN, MOG.A, MOG.B Downgrades: BSX, DOC, FCE.A, FCE.B, ICCC Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
¿ $75M transaction enhances manufacturing expertise in structural heart
In a record year for acquisitions, 18 companies from across the spectrum were singled out by M&A professionals for doing deals that got results.
In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Boston Scientific Corp. has taken over the #76 spot from Sherwin-Williams Co , according to ETF Channel.
Late-Breaking Trial Data Presented at AHA Scientific Sessions Demonstrate Success of Alert to Predict Worsening Heart Failure
Acquisition Advances Treatment Options for Women with Uterine Polyps
Technology to Improve Management of Gastrointestinal Diseases
Late-Breaking Trial Data Presented at TCT Scientific Sessions and Simultaneously Published in the Journal of the American College of Cardiology
The PLATINUM Diversity Study Provides Much Needed Data about Women and Minority Patients, Who are Under-represented in Cardiology Clinical Trials
Jim Cramer likes SWHC and BX, but not NAT and DBD.
Cramer previews important earnings reports scheduled for the coming week.
Boston Scientific reported earnings of $0.27, in-line with analyst expectations.
Boston Scientific (BSX) reported 2016 third-quarter revenue that exceeded analysts' expectations and raised its full-year revenue forecast.
The medical devices company is likely to stick to small- to mid- sized M&A unless it finds itself the target.
Before Wednesday's market open Boston Scientific (BSX) will post 2016 third quarter results.
Launch of Hemostasis Clip Advances Innovation within the Field of Endoscopy
Acquisition Will Expand Endoscopy Gastroenterology Portfolio
Cramer will be monitoring earnings and the Federal Reserve next week.
Demand is quite healthy and markets are not going into the abyss, Cramer says.
Pay attention to what companies are doing to improve themselves, not the hand-wringing from fund managers about Fed intervention.